Abstract: An antimicrobial article, a cell culture article, an antithrombotic article, or a biopharmaceutical article that can reduce adhesion of proteins, blood components, cells, or bacteria containing a copolymer that contains a polymerized unit (A) represented by —CH2—CHOH— and a polymerized unit (B) represented by —CH2—CX2—, wherein Xs are the same as or different from each other, and are each an alkyl group having a linear, branched, or cyclic structure, and optionally containing an oxygen atom between carbon atoms, an alkoxy group having a linear, branched, or cyclic structure, and optionally containing a hetero atom between carbon atoms, a siloxy group having a carbon number of 3 or greater, an ester group containing an aromatic ring or an alkyl group and having a linear, branched, or cyclic structure, or H, excluding those in which both Xs are H.

Abstract: A non-tubular material for nerve regeneration induction, which can be used for the regeneration of a damaged part in a nerve, and which comprises: (A) a crosslinked form produced by crosslinking a low-endotoxin bioabsorbable polysaccharide having a carboxyl group in the molecule with at least one crosslinkable reagent selected from a compound represented by general formula (I) and a salt thereof via covalent bonds; and (B) a bioabsorbable polymer. R1HN—(CH2)n—NHR2 (I) [wherein R1 and R2 independently represent a hydrogen atom or a group represented by formula: —COCH(NH2)—(CH2)4—NH2, and n represents an integer of 2 to 18]. Thus, a medical material that can induce the regeneration of a damaged part in a nerve is provided.

Abstract: A non-tubular material for nerve regeneration induction, which can be used for the regeneration of a damaged part in a nerve, and which comprises: (A) a crosslinked form produced by crosslinking a low-endotoxin bioabsorbable polysaccharide having a carboxyl group in the molecule with at least one crosslinkable reagent selected from a compound represented by general formula (I) and a salt thereof via covalent bonds; and (B) a bioabsorbable polymer. R1HN—(CH2)n—NHR2 (I) [wherein R1 and R2 independently represent a hydrogen atom or a group represented by formula: —COCH(NH2)—(CH2)4—NH2, and n represents an integer of 2 to 18]. Thus, a medical material that can induce the regeneration of a damaged part in a nerve is provided.

Abstract: Provided is a non-tubular brain damage recovery material which is used to cover and/or fill a damaged part of the brain, the brain damage recovery material including: (A) a cross-linked body with which a bioabsorbable polysaccharide having a carboxyl group in a low endotoxin molecule is covalently bonded and cross-linked with at least one crosslinking reagent selected from among a compound represented by general formula (I) and salts thereof; and (B) a bioabsorbable polymer. R1HN—(CH2)n—NHR2 (I) [in the formula, R1 and R2 each independently represent a hydrogen atom or a group represented by formula of —COCH(NH2)—CH2]4—NH2, and n represents an integer from 2 to 18]. Accordingly, provided is a medical material which can recover a damaged part of the brain.

Abstract: An antimicrobial article, a cell culture article, an antithrombotic article, or a biopharmaceutical article that can reduce adhesion of proteins, blood components, cells, or bacteria containing a copolymer that contains a polymerized unit (A) represented by —CH2—CHOH— and a polymerized unit (B) represented by —CH2—CX2—, wherein Xs are the same as or different from each other, and are each an alkyl group having a linear, branched, or cyclic structure, and optionally containing an oxygen atom between carbon atoms, an alkoxy group having a linear, branched, or cyclic structure, and optionally containing a hetero atom between carbon atoms, a siloxy group having a carbon number of 3 or greater, an ester group containing an aromatic ring or an alkyl group and having a linear, branched, or cyclic structure, or H, excluding those in which both Xs are H.

Abstract: A non-tubular material for nerve regeneration induction, which can be used for the regeneration of a damaged part in a nerve, and which comprises: (A) a crosslinked form produced by crosslinking a low-endotoxin bioabsorbable polysaccharide having a carboxyl group in the molecule with at least one crosslinkable reagent selected from a compound represented by general formula (I) and a salt thereof via covalent bonds; and (B) a bioabsorbable polymer. R1HN—(CH2)n—NHR2 (I) [wherein R1 and R2 independently represent a hydrogen atom or a group represented by formula: —COCH(NH2)—(CH2)4—NH2, and n represents an integer of 2 to 18]. Thus, a medical material that can induce the regeneration of a damaged part in a nerve is provided.

Abstract: Disclosed is a compound which exhibits a higher effect of preventing wrinkle formation, a higher effect of improving wrinkles, a higher effect of making the skin beautiful, and a higher effect of improving skin quality than conventional retinol and retinol derivatives in a sustained manner. Further disclosed are a method for producing the same, and an external composition for the skin and a sheet-shaped cosmetic each containing the same as an active ingredient. More specifically disclosed are retinol-modified collagen in which a dicarboxylic acid is attached to at least one hydroxyl group of collagen and retinol is attached to a carboxyl group of at least one attached dicarboxylic acid, a method for producing the same, and an external composition for the skin and a sheet-shaped cosmetic each containing the same as an active ingredient.

Abstract: Disclosed is a compound which exhibits a higher effect of preventing wrinkle formation, a higher effect of improving wrinkles, a higher effect of making the skin beautiful, and a higher effect of improving skin quality than conventional retinol and retinol derivatives in a sustained manner. Further disclosed are a method for producing the same, and an external composition for the skin and a sheet-shaped cosmetic each containing the same as an active ingredient. More specifically disclosed are retinol-modified collagen in which a dicarboxylic acid is attached to at least one hydroxyl group of collagen and retinol is attached to a carboxyl group of at least one attached dicarboxylic acid, a method for producing the same, and an external composition for the skin and a sheet-shaped cosmetic each containing the same as an active ingredient.

Abstract: The present invention provides a novel polypeptide or polypeptide derivative which has no risk of infection with a pathogen or propagation of a pathogenic factor and of an undesirable side effect, and which is useful as a carrier of various biologically-active substances or apatite, as well as a process for producing the same. More particularly, the present invention provides a polypeptide comprising a peptide unit having an amino acid sequence represented by the formula: -Pro-X-Gly- (wherein X represents Pro or Hyp) and a peptide unit having an amino acid sequence represented by the formula: -Pro-Hyp(O—Y—Z)-Gly- (wherein Y represents a carbonyl group, a saturated or unsaturated hydrocarbon group with or without a carbonyl group, or a saturated or unsaturated hydrocarbon group with or without a carbonyl group, including an aromatic group, and Z represents a carboxyl group), as well as a process for producing the same.

Abstract: The present invention aims at providing a biomaterial composite not having risks of pathogen infection and unfavorable side effects such as rejection response. According to the invention, there is provided a biomaterial composite, which comprises a polypeptide and a calcium phosphate compound, said peptide comprising the units of Formulas (I) to (III): [—(OC—(CH2)m—CO)p-(Pro-Y-Gly)n-]a??(I) [—(OC—(CH2)m—CO)q-(z)r-]b??(II) [—HN—R—NH—]c??(III) wherein m, p, q, Y, n, Z, r, R, a, b and c are as defined in the specification. The composite of the invention is particularly suitable for an artificial bone due to its high biocompatibility, high endurance and mechanical strength. Further, the invention can provide a process of the composite according to the invention can for preparation of the composite having excellent mechanical characteristics by a simple procedure.

Abstract: The present invention provides a novel polypeptide or polypeptide derivative which has no risk of infection with a pathogen or propagation of a pathogenic factor and of an undesirable side effect, and which is useful as a carrier of various biologically-active substances or apatite, as well as a process for producing the same. More particularly, the present invention provides a polypeptide comprising a peptide unit having an amino acid sequence represented by the formula: -Pro-X-Gly- (wherein X represents Pro or Hyp) and a peptide unit having an amino acid sequence represented by the formula: -Pro-Hyp(O—Y—Z)-Gly- (wherein Y represents a carbonyl group, a saturated or unsaturated hydrocarbon group with or without a carbonyl group, or a saturated or unsaturated hydrocarbon group with or without a carbonyl group, including an aromatic group, and Z represents a carboxyl group), as well as a process for producing the same.

Abstract: A process for producing a polypeptide, by reacting a peptide component (A) represented by formula (1) below with a peptide component (B) represented by formula (2) below and optionally a compound (C) represented by formula (3) below, to obtain said polypeptide: (1) X-(Pro-Y-Gly)n-OH, wherein: X represents H or the group HOOC—(CH2)m—CO— and m denotes an integer of 1 to 18, Y represents Pro or Hyp, and n denotes an integer of 1 to 20; (2) X-(Z)r—OH, wherein X represents H or the group HOOC—(CH2)m—CO— and m denotes an integer of 1 to 18, Z represents a peptide chain comprising 1 to 10 amino acid residue(s), and r denotes an integer of 1 to 20; and (3) H2N—R—NH2, wherein R represents a linear or branched alkylene group; and further wherein the ratio of the peptide component (A) relative to the peptide component (B) is 100/0 to 30/70 (mol %); provided that in the case where X represents the group HOOC—(CH2)m—CO— and m has the same meaning as defined above in formula (1) and/or (2), the amount of compou

Abstract: The object is to provide a novel heparin alternative material, which is excellent in safety and in vivo degradability. Disclosed are: a novel heparin alternative material, which comprises an enzymatically synthesized ?-1,4-glucan derivative and has functions substituting those of heparin, such as an anticoagulation activity and functions of a material for storage or sustained release of a heparin-binding growth factor; a method for production of the substitute material; and a preparation or article for medical applications or a cosmetic produced using the heparin alternative material.

Abstract: The present invention aims at providing a biomaterial composite not having risks of pathogen infection and unfavorable side effects such as rejection response. According to the invention, there is provided a biomaterial composite, which comprises a polypeptide and a calcium phosphate compound, said peptide comprising the units of Formulas (I) to (III): [—(OC—(CH2)m—CO)p-(Pro-Y-Gly)n-]a??(I) [—(OC—(CH2)m—CO)p-(z)r-]b??(II) [—HN—R—NH—]c??(III) wherein m, p, q, Y, n, Z, r, R, a, b and c are as defined in the specification. The composite of the invention is particularly suitable for an artificial bone due to its high biocompatibility, high endurance and mechanical strength. Further, the invention can provide a process of the composite according to the invention can for preparation of the composite having excellent mechanical characteristics by a simple procedure.

Abstract: A peptide component (A) represented by the following formula (1a) with a peptide component (B) represented by the following formula (2a) and a compound (C) represented by the following formula (3a), as an optional component are subjected to a condensation reaction in the presence of a dehydrating and condensing agent and a condensing auxiliary; provided that in the case where “X” represents HOOC—(CH2)m—CO— in the formula (1a) and/or (2a), the reaction is conducted with the compound (C). The ratio of the peptide component (A) relative to the peptide component (B) is 100/0 to 30/70 (mol %), and the ratio of the compound (C) relative to the total molar amount of the peptide component (A) and/or the peptide component (B).

Abstract: The present invention provides a hemostatic material which is excellent in hemostatic property, biodegradability and bioabsorbability, uniformity and stability of the quality, as well as reduces a risk of contamination with a pathogenic organism derived from an animal. The hemostatic material comprises a thrombin and a synthetic polypeptide capable of forming a triple helical structure. The polypeptide may show a peak of the molecular weight in the range from 5×104 to 100×104 in the molecular weight distribution. The polypeptide may contain at least a peptide unit represented by the formula: -Pro-X-Gly- (in the formula, X represents Pro or Hyp). The thrombin may be a recombinant. In the hemostatic material, the proportion of the thrombin may be about 0.1 to 500 units (U) relative to 1 mg of the polypeptide. The hemostatic material may further comprise a binder component having biodegradability and bioabsorbability. The hemostatic material may be formed on a substrate.

Abstract: The present invention provides a bioapplicable material (or composition) or film-forming material (or composition), which is free from a risk of an infection by a pathogenic organism or a transmission of a causative factor, has a high safety. The material (or composition) comprises a collagen-like synthetic polypeptide having at least an amino acid sequence represented by the formula -Pro-Y-Gly- (wherein Y represents Pro or Hyp). The polypeptide may show positive Cotton effect at a wavelength in range of 220 to 230 nm and negative Cotton effect at a wavelength in range of 195 to 205 nm in a circular dichroism spectrum. At least part of the polypeptide may be capable of forming a triple helical structure. The polypeptide may be degradable with a collagenase.

Abstract: The present invention provides a novel biodegradable and biosorbable polypeptide which is free from a risk of an infection by a pathogenic organism or a transmission of a causative factor, or a risk of an undesirable side effect, and a process for producing the same, as well as a collagenase inhibitor comprising the polypeptide and having a high collagenase inhibitory action. The polypeptide contains a peptide unit having an amino acid sequence represented by the following formula (1), and a peptide unit having an amino acid sequence represented by the following formula (2): -Pro-X-Gly-??(1) -Pro-Y-Gly-Z-Ala-Gly-??(2) wherein X represents Pro or Hyp; Y represents Gln, Asn, Leu, Ile, Val or Ala; and Z represents Ile or Leu. The molar ratio of the peptide unit (1) relative to the peptide unit (2) is about 99/1 to 1/99.

Abstract: The invention provides for a polypeptide, which is useful as a biomaterial and free from infection. The polypeptide comprises a peptide unit of formula (1), and optionally one or more units of formulae (2) to (3): (1) [—(OC—(CH2)m—CO)p-(Pro-Y-Gly)n-]a; (2) [—(OC—(CH2)m—CO)q-(Z)r-]b; and (3) [—HN—R—NH—]c, wherein “m” is 1-18 , “p” and “q” are identical or different, and each is 0 or 1 , “Y” is Pro or Hyp, and “n”1-20 ; “Z” is a peptide chain comprising 1-10 amino acids, “r”1-20 , and “R” is a linear or branched alkylene group; the molar ratio of “a” to “b”[a/b] is 100/0 to 30/70 ; when p=1 and q=0, c=a, when p=0 and q=1, c=b, when p=1 and q=1, c=a+b, and when p=0 and q=0, c=0; and the polypeptide shows a peak of molecular weight in a range from 1×104 to 100×104 in the molecular weight distribution.

Abstract: A peptide has at least an amino acid sequence represented by SEQ ID NO:1 and it has an osteogenetic activity.